296 related articles for article (PubMed ID: 15647217)
1. Surrogate endpoints and FDA's accelerated approval process.
Fleming TR
Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
[TBL] [Abstract][Full Text] [Related]
2. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
[TBL] [Abstract][Full Text] [Related]
3. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE; Farrell AT; Pazdur R; Woodcock J
Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
[TBL] [Abstract][Full Text] [Related]
4. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
5. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
[TBL] [Abstract][Full Text] [Related]
6. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
Orlando VI
Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
[No Abstract] [Full Text] [Related]
7. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process.
Pinco RG
Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327
[No Abstract] [Full Text] [Related]
8. Accelerated approval of oncology products: a decade of experience.
Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
[TBL] [Abstract][Full Text] [Related]
9. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
[No Abstract] [Full Text] [Related]
10. The food and drug administration and molecular imaging agents: potential challenges and opportunities.
Henderson JA; Alexander BC; Smith JJ
J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943
[TBL] [Abstract][Full Text] [Related]
11. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
Merkatz RB
J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
[No Abstract] [Full Text] [Related]
12. Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.
Rasnake CM; Trumbo PR; Heinonen TM
Nutr Rev; 2008 Feb; 66(2):76-81. PubMed ID: 18254873
[TBL] [Abstract][Full Text] [Related]
13. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
14. FDA reform: new Senate bill. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
[TBL] [Abstract][Full Text] [Related]
15. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
16. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
Rulis AM; Levitt JA
Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
[TBL] [Abstract][Full Text] [Related]
17. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
18. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
19. Hepatology may have problems with putative surrogate outcome measures.
Gluud C; Brok J; Gong Y; Koretz RL
J Hepatol; 2007 Apr; 46(4):734-42. PubMed ID: 17316871
[TBL] [Abstract][Full Text] [Related]
20. FDA policy on unapproved drug products: past, present, and future.
Chhabra R; Kremzner ME; Kiliany BJ
Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
